Iroko Pharmaceuticals has acquired all non-U.S. commercial rights to Aggrastat (tirofiban HCl) from Merck.
Outside of the U.S. market, Aggrastat, in combination with heparin, is indicated for patients with unstable angina or non-Q wave MI to prevent cardiac ischemic events, and is also indicated for patients with coronary ischemic syndromes undergoing coronary angioplasty or atherectomy to prevent cardiac ischemic complications related to abrupt closure of the treated coronary artery, the Philadelphia-based Iroko said.
Aggrastat is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and the undergoing percutaneous transluminal coronary angioplasty, according to the company.
Iroko said that the acquisition will lead to revenue of $100 million annually.
The financial terms were not disclosed by either company.